

Sterling Biotech Limited
Registered Office : 43, Atlanta Building, Nariman Point, Mumbai - 400 021.
UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE THIRD QUARTER ENDED 30th SEPTEMBER, 2007

(Rs. In Lakhs)

Sr. No.	Particulars	3 months ended (30/09/2007)	Corresponding 3 months ended in the previous year (30/09/2006)	Year to Date figures for current Period ended (30/09/2007)	Year to date figures for the previous year ended (30/09/2006)	Previous accounting year ended (31/12/2006)
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/Income from Operations	24,845.64	16,096.89	64,955.24	43,755.93	60,585.36
2	Other Income	253.19	111.18	732.87	287.79	504.52
3	Total Income (1+2)	25,098.83	16,208.07	65,688.11	44,043.72	61,089.88
4	Expenditure					
	a Increase/decrease in stock in trade and work in progress	(2,917.64)	(374.67)	(6,164.21)	(845.12)	(1,268.81)
	b Consumption of raw materials	11,656.22	5,714.94	28,402.98	15,171.40	20,997.60
	c Purchase of traded goods	0.00	0.00	0.00	0.00	0.00
	d Employees Cost	563.86	436.07	1,500.64	1,186.08	1,626.88
	e. Depreciation	2,540.73	1,766.99	6,474.67	4,423.94	6,202.55
	f. Other expenditure	4,402.69	2,516.66	11,534.19	7,431.09	10,509.47
	g. Total	16,245.86	10,059.99	41,748.27	27,367.39	38,067.69
5	Interest	1,018.51	1,029.52	3,037.88	3,088.63	4,116.70
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit(+)/Loss (-) from Ordinary Activities before tax (3) - (4+5+6)	7,834.46	5,118.56	20,901.96	13,587.70	18,905.49
8	Tax expense					
	a) Current	850.00	480.00	2,215.00	1,350.00	1,900.00
	b) Deferred	1,675.00	825.00	4,250.00	2,000.00	2,850.00
	c) Fringe Benefit	6.12	8.63	17.99	26.06	30.75
	d) Total	2,531.12	1,313.63	6,482.99	3,376.06	4,780.75
9	Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)	5,303.34	3,804.93	14,418.97	10,211.64	14,124.74
10	Extraordinary Items	320.11	161.29	801.51	483.87	645.14
11	Net Profit (+)/Loss (-) for the period (9-10)	4,983.23	3,643.64	13,617.46	9,727.77	13,479.60
12	Paid-up equity share capital (Face Value of Rs.1/- per share)	2,289.02	2,212.49	2,289.02	2,212.49	2,223.48
13	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.					99,048.80
14	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary itmes for the period, for the year to date and for the previous year	2.32	1.72	6.30	4.62	6.35
	b) Basic and diluted EPS after Extraordinary itmes for the period, for the year to date and for the previous year	2.18	1.65	5.95	4.40	6.06
15	Public Shareholding					
	- Number of shares	150,929,206	151,026,858	150,929,206	151,026,858	152,125,969
	- Percentage of shareholding	65.94%	68.26%	65.94%	68.26%	68.42%

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above financial results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 31st October, 2007.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30th September, 2007.
- 4 The number of investor complaints for the quarter ended on 30th September, 2007 were :
Openging - 7, Received - 17, Disposed off - 21, and Balance - 03.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 31st October, 2007

Nitin J. Sandesara
Chairman & Managing Director